Grafa
Summit reports HARMONi survival hazard ratio of 0.76
Image for illustrative purposes only. Not a real photo.

Summit reports HARMONi survival hazard ratio of 0.76

Share
  • Summit reported an overall-survival hazard ratio of 0.76 in the updated Phase III HARMONi analysis.
  • Summit shares were up 8.3% at $14.63 in premarket trading following the announcement.
  • The company submitted the updated results to the FDA ahead of its November 14, 2026, regulatory decision target.

Summit Therapeutics (NASDAQ:SMMT) reported a 0.76 overall-survival hazard ratio in its updated global Phase III HARMONi analysis submitted to the FDA.

The ratio improved from 0.79 in April 2025 and 0.78 in September 2025 as follow-up among western patients increased.

The June analysis included 23.2 months of western follow-up, but Summit has not disclosed updated median survival or confidence intervals.

Following the announcement, Summit Therapeutics's share price was up 8.3% at $14.63 in premarket trading.

Summit’s FDA application seeks approval for ivonescimab plus chemotherapy, with a regulatory decision targeted for November 14, 2026.

HARMONi previously showed median survival of 16.8 months versus 14.0 months and a statistically significant progression-free-survival benefit.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.